MagnetisMM-1: Efficacy, Safety, and Tolerability of Subcutaneous Elranatamab in Patients With Relapsed/Refractory Multiple Myeloma

June 4-8, 2021; Online at https://conferences.asco.org/am
Subcutaneous elranatamab, a BCMA-/CD3-targeted bispecific antibody, had a manageable safety profile and encouraging activity in relapsed/refractory multiple myeloma as reported in the MagnetisMM-1 phase I trial.
Format: Microsoft PowerPoint (.ppt)
File Size: 456 KB
Released: June 14, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
AstraZeneca
Bristol-Myers Squibb
GlaxoSmithKline
Novartis Pharmaceuticals Corporation
Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.
Sanofi Genzyme

Related Content

Drs David Kuter and Catherine M. Broome review the latest available clinical data for emerging therapy options for ITP, from Clinical Care Options (CCO)

person default Catherine M. Broome, MD David J. Kuter, MD, DPhil Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: August 5, 2021 Expired: August 4, 2022

From Clinical Care Options (CCO), Caron Jacobson, MD, discusses best practices in managing delayed toxicities associated with CAR T-cell therapy

person default Caron A. Jacobson, MD Released: August 5, 2021

From Clinical Care Options (CCO), download slides reviewing key CAR T-cell therapy considerations for managed care and specialty pharmacy professionals

person default Craig Freyer, PharmD Zahra Mahmoudjafari, PharmD, BCOP, DPLA Released: August 4, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue